Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Scientists reveal cancer cells' immune weak spot

Scientists reveal cancer cells' immune weak spot

Removing tumor's protective wall could help boost the effects of cancer treatments

Removing tumor's protective wall could help boost the effects of cancer treatments

Researchers target cancer's protective barrier

Researchers target cancer's protective barrier

Needle stick injuries are common and can transmit many blood-borne pathogens

Needle stick injuries are common and can transmit many blood-borne pathogens

New insight into the immune system may help doctors to better fight cancer

New insight into the immune system may help doctors to better fight cancer

Uchicago Medicine oncologist to receive 2019 Henry M. Stratton Medal for hematology research

Uchicago Medicine oncologist to receive 2019 Henry M. Stratton Medal for hematology research

UAMS Myeloma Center receives $542,486 grant from Leukemia & Lymphoma Society

UAMS Myeloma Center receives $542,486 grant from Leukemia & Lymphoma Society

People who have a parent, sibling, or child with blood cancer have higher risk of disease

People who have a parent, sibling, or child with blood cancer have higher risk of disease

Stimulating immune cells with nanosecond pulsed electric fields can cause them to respond

Stimulating immune cells with nanosecond pulsed electric fields can cause them to respond

Beckman Coulter Life Sciences publishes ClearLLab Control Cells white paper

Beckman Coulter Life Sciences publishes ClearLLab Control Cells white paper

New 'bone in a dish' could help explore fundamental disease processes

New 'bone in a dish' could help explore fundamental disease processes

New drug combination successfully reduces levels of bovine leukemia virus

New drug combination successfully reduces levels of bovine leukemia virus

New leukemia treatment developed from common wild flower

New leukemia treatment developed from common wild flower

Study confirms link between treatment results and frequency of service provided

Study confirms link between treatment results and frequency of service provided

Clinical cell therapy expert shares the benefits of donating cord blood

Clinical cell therapy expert shares the benefits of donating cord blood

Combination therapy could be a promising treatment for late-stage acute lymphoblastic leukemia

Combination therapy could be a promising treatment for late-stage acute lymphoblastic leukemia

Scientists discover novel mechanism of action for NK cells in checkpoint inhibitor for cancer

Scientists discover novel mechanism of action for NK cells in checkpoint inhibitor for cancer

An unexpected developmental hierarchy in a rare disease affecting young children

An unexpected developmental hierarchy in a rare disease affecting young children

CAR-T cells used to target glioblastoma

CAR-T cells used to target glioblastoma

Researchers develop new compound to block therapeutic target in aggressive blood cancer

Researchers develop new compound to block therapeutic target in aggressive blood cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.